Filtered By:
Condition: Thrombosis
Drug: Activase

This page shows you your search results in order of relevance. This is page number 15.

Order by Relevance | Date

Total 351 results found since Jan 2013.

Early recanalization with intravenous thrombolysis before mechanical thrombectomy: considerations to explore with tenecteplase
Time is brain. Hence, timely reperfusion in emergent large vessel occlusion (LVO) stroke is critical for favorable outcomes. Intravenous thrombolysis with alteplase (TPA) before mechanical thrombectomy (MT) for emergent LVO stroke is associated with significantly higher rates of preinterventional reperfusion than MT alone. Recent post hoc analyses of SWIFT-DIRECT and DIRECT-MT have shown that times longer than 30 min since TPA administration are associated with increased reperfusion rates.1 2 The incremental increase of reperfusion rates with longer times since TPA administration underpins TPA’s time dependence to ex...
Source: Journal of NeuroInterventional Surgery - April 13, 2023 Category: Neurosurgery Authors: Hendrix, P., Schirmer, C. M. Tags: Letter Source Type: research

Thrombosis in Continuous‐Flow Left Ventricular Assist Devices: Pathophysiology, Prevention, and Pharmacologic Management
Continuous‐flow left ventricular assist devices reduce short‐term mortality and improve quality of life in patients with end‐stage heart failure. Unfortunately, device‐related complications remain common, with many patients experiencing adverse events within the first year. New literature suggests that rates of device‐related thrombosis may be increasing since 2011, which is particularly troublesome given that this pathology can result in a disabling stroke, organ damage, and death. In 2013, a group of practitioners in the field of mechanical circulatory support published a treatment algorithm based on their expe...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - October 20, 2014 Category: Drugs & Pharmacology Authors: Douglas L. Jennings, Phillip A. Weeks Tags: Review of Therapeutics Source Type: research

The free-radical scavenger edaravone accelerates thrombolysis with alteplase in an experimental thrombosis model
Reperfusion injury after thrombolytic therapy can have adverse neurologic effects. The free-radical scavenger edaravone is used in combination with the recombinant tissue plasminogen activator alteplase to treat acute ischemic stroke. However, basic investigations of this combination use remain inadequate. Here, we used an in vivo model to investigate the effects of edaravone on alteplase-induced thrombolysis.
Source: Thrombosis Research - April 13, 2015 Category: Hematology Authors: Tsutomu Yamashita, Takumi Sato, Kumi Sakamoto, Hiromitsu Ishii, Junichiro Yamamoto Tags: Regular article Source Type: research

Progress in Intravenous Thrombolytic Therapy for Acute Stroke
This review traces the development of intravenous thrombolysis to date, considers the shortcomings of alteplase, and examines alternative thrombolytic approaches currently in the pipeline, including the role of neuroimaging and the possibility of combination therapies.
Source: JAMA Neurology - June 1, 2015 Category: Neurology Source Type: research

May 18, 2018 This Week in Cardiology May 18, 2018 This Week in Cardiology
Device-related thrombosis with Watchman left atrial appendage closure, debulking atrial fibrillation after ablation, rivaroxaban for stroke prevention, alteplase, and Lp(a) are discussed this week.theheart.org on Medscape
Source: Medscape Today Headlines - May 18, 2018 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Symptomatic Intracerebral Hemorrhage after Intravenous Thrombolysis: Predictive Factors and Validation of Prediction Models
Objective: Thrombolytic therapy with intravenous alteplase (IV-rtPA) has a known risk of symptomatic intracerebral hemorrhage (sICH). We aim to identify factors with a significant association with the development of sICH post-IV-rtPA. We also aim to perform an external validation of sICH predicting scores in our patient population. Material and Methods: We performed a retrospective chart review of patients who received IV-rtPA at our tertiary care hospital. We excluded patients who underwent mechanical thrombectomy.
Source: Journal of Stroke and Cerebrovascular Diseases - September 5, 2019 Category: Neurology Authors: Taha Nisar, Rajanigandhi Hanumanthu, Priyank Khandelwal Source Type: research

Bacterial staphylokinase as a promising third-generation drug in the treatment for vascular occlusion.
Abstract Vascular occlusion is one of the major causes of mortality and morbidity. Blood vessel blockage can lead to thrombotic complications such as myocardial infarction, stroke, deep venous thrombosis, peripheral occlusive disease, and pulmonary embolism. Thrombolytic therapy currently aims to rectify this through the administration of recombinant tissue plasminogen activator. Research is underway to design an ideal thrombolytic drug with the lowest risk. Despite the potent clot lysis achievable using approved thrombolytic drugs such as alteplase, reteplase, streptokinase, tenecteplase, and some other fibrinoly...
Source: Molecular Biology Reports - October 31, 2019 Category: Molecular Biology Authors: Nedaeinia R, Faraji H, Javanmard SH, Ferns GA, Ghayour-Mobarhan M, Goli M, Mashkani B, Nedaeinia M, Haghighi MHH, Ranjbar M Tags: Mol Biol Rep Source Type: research

M2 segment thrombectomy is not associated with increased complication risk compared to M1 segment: A meta-analysis of recent literature
Numerous trials report safety and efficacy of mechanical thrombectomy (MT) for infarcts involving the M1 segment of the middle cerebral artery (MCA; extending from the terminal bifurcation of the internal carotid artery proximally to the main bifurcation distally) in comparison to intravenous thrombolytic therapy (e.g. alteplase) therapy alone.1 –5 The Highly Effective Reperfusion Using Multiple Endovascular Devices (HERMES) meta-analysis of these early studies reported a number needed to treat of 2.6 for MT to reduce the modified Rankin Scale (mRS) by 1 point.
Source: Journal of Stroke and Cerebrovascular Diseases - August 15, 2020 Category: Neurology Authors: Christopher Alexander, Andrew Caras, William Kyle Miller, Rizwan Tahir, Tarek R. Mansour, Azedine Medhkour, Horia Marin Source Type: research

Systemic tPA Treatment for Thrombosis in a Patient with Dilated Cardiomyopathy on Berlin Heart
We present a case of thrombosis in a patient on Berlin Heart LVAD that was successfully treated with systemic alteplase.
Source: The Journal of Heart and Lung Transplantation - March 20, 2021 Category: Transplant Surgery Authors: L.D. Glass, R. Murthy, P. Pastuszko Tags: (1357) Source Type: research

Reduced-dose intravenous thrombolysis for acute intermediate high-risk pulmonary embolism: Rationale and design of the PEITHO-3 trial
Thromb Haemost. 2021 Sep 24. doi: 10.1055/a-1653-4699. Online ahead of print.ABSTRACTIntermediate high-risk pulmonary embolism (PE) is characterised by right ventricular (RV) dysfunction and elevated circulating cardiac troponin levels despite apparent haemodynamic stability at presentation. In these patients, full-dose systemic thrombolysis reduced the risk of haemodynamic decompensation or death but increased the risk of life-threatening bleeding. Reduced-dose thrombolysis may be capable of improving safety while maintaining reperfusion efficacy. The Pulmonary Embolism International Trial (PEITHO)-3 study (EudraCT 2018-0...
Source: Thrombosis and Haemostasis - September 24, 2021 Category: Hematology Authors: Olivier Sanchez Anais Charles-Nelson Walter Ageno Stefano Barco Harald Binder Gilles Chatellier Daniel Duerschmied Klaus Empen Melanie Ferreira Philippe Girard Menno V Huisman David Jim énez Sandrine Katsahian Matija Kozak Mareike Lankeit Nicolas Menevea Source Type: research

Impact of poly-arginine peptides R18D and R18 on alteplase and tenecteplase thrombolysis in vitro, and neuroprotective stability to proteolysis
AbstractThe poly-arginine peptides R18D and R18 represent novel potential neuroprotective treatments for acute ischaemic stroke. Here we examined whether R18D and R18 had any significant effects on the thrombolytic activity of alteplase (tPA) and tenecteplase (TNK) on clots formed from whole blood in an in vitro thrombolysis plate assay. R18D and R18 were examined at concentrations of 0.25, 0.5, 1, 2, 4, 8 and 16  µM during the 1-h thrombolytic assay. We also included the well-characterised neuroprotective NA-1 peptide as a control. R18D, R18 and NA-1 all reduced tPA or TNK percentage clot lysis by 0–9.35%, 0–3.44% a...
Source: Journal of Thrombosis and Thrombolysis - March 19, 2022 Category: Hematology Source Type: research

Anterograde Injection of Alteplase Salvages Deep Inferior Epigastric Perforator Flap in Reconstructive Breast Surgery
We report the case of a 43-year-old woman who underwent unilateral breast reconstruction with a DIEP flap at our department. Approximately 12 hours postoperatively, an arterial inflow problem was suspected and revision surgery was performed. Peripheral flap perfusion remained absent without an obvious cause and distal thrombosis was assumed to be present. Therefore, alteplase was gradually injected into the arterial pedicle in the anterograde direction just distal to the anastomosis while clamping the artery proximally. About 3 hours after selective flap thrombolysis, microcirculation of the flap was successfully restored ...
Source: Plastic and Reconstructive Surgery Global Open - June 1, 2022 Category: Cosmetic Surgery Tags: Breast: Case Report Source Type: research

Immediate outcome prognostic value of plasma factors in patients with acute ischemic stroke after intravenous thrombolytic treatment
In the present study, we explored multiple plasma factors to predict the outcomes of patients with AIS after IVT. Fifty AIS patients who received IVT with alteplase were recruited and divided into two groups a...
Source: BMC Neurology - September 20, 2022 Category: Neurology Authors: Huanhuan Lu, Siyi Li, Xin Zhong, Shuxuan Huang, Xue Jiao, Guoyong He, Bingjian Jiang, Yuping Liu, Zhili Gao, Jinhong Wei, Yushen Lin, Zhi Chen and Yanhua Li Tags: Research Source Type: research

Effectiveness of alteplase intravenous thrombolysis combined with butylphthalide in patients with acute severe cerebral infarction
CONCLUSIONS: Alteplase intravenous thrombolysis combined with butylphthalide in the treatment of severe cerebral infarction is safe, and may significantly improve patient's neurological function and quality of life without adverse reactions.PMID:36734384 | DOI:10.5114/fn.2022.118787
Source: Folia Neuropathologica - February 3, 2023 Category: Pathology Authors: Zhengqian Wang Junshuang Che Source Type: research